Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOCoV2
2020-002120-37Phase 2Unknown
- Sponsor
- Thirty Respiratory Limited
- Start
- Jun 2020
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing RESP301 plus standard of care with Standard of care alone (2 arms). Primary endpoint: Progression to modified WHO ordinal scale level greater than 4 by Day 14. Status: unknown.
02
Drugs
RESP301
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002120-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002120-37.